Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Blood Specimen Collection × NET × 30 days × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Breast 11 Genitourinary 9 Gastrointestinal 8 Tumor-Agnostic 4 Dermatologic 4 CNS 4 Thoracic 3 Gynecologic 3 Lymphoid 2 Endocrine 2 Sarcoma 1 Plasma cell 1 Other solid neoplasm 1 Other hematologic neoplasm 1 NET 1 Myeloid 1 Head & Neck 1 Classical hematology 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 11 Specimen Handling 6 Magnetic Resonance Spectroscopy 6 Everolimus 6 cabozantinib 5 olaparib 3 X-Rays 3 lanreotide 2 avelumab 2 Sunitinib 2 Phantoms, Imaging 2 Octreotide 2 Nivolumab 2 Lutetium-177 2 surufatinib 1 repotrectinib 1 peposertib 1 pembrolizumab 1 pazopanib 1 pasireotide 1 lenvatinib 1 gallium Ga 68 dotatate 1 fludarabine 1 belinostat 1 amino-acid, glucose, and electrolyte solution 1 aldesleukin 1 Tomography, X-Ray Computed 1 Tomography, Emission-Computed, Single-Photon 1 Single Photon Emission Computed Tomography Computed Tomography 1 Salts 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06430021 2026-03-24

PRO-NEM1

Centre Hospitalier Universitaire Dijon

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡